Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  DaVita    DVA


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Bridgepoint tests appetite for $2.2 billion dialysis clinic firm Diaverum - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
07/30/2019 | 11:53am EDT

FRANKFURT/LONDON (Reuters) - European buyout firm Bridgepoint is exploring a sale or stock market listing of its dialysis clinic operator Diaverum as part of a long-anticipated exit plan that could fetch up to 2 billion euros ($2.23 billion or £1.83 billion), sources close to the matter told Reuters.

The London-based buyout group has hired JP Morgan and SEB to prepare the company for a sale or listing, with a view to starting a formal dual-track process early next year, the sources said.

But the banks will start sounding out prospective bidders after the summer break, they said, as part of their pre-marketing work to establish if there is sufficient interest to launch a process.

Bridgepoint declined to comment.

Representatives at JPMorgan and SEB were not immediately available for comment.

Based in the Swedish city of Malmo, Diaverum ranks as Europe's largest independent dialysis clinic operator, with ancillary businesses in South America and Australia.

Earlier this year it signed a new five-year dialysis contract with the Ministry of Health in Saudi Arabia, which the company hopes will boost its business.

Bridgepoint has held the company for more than a decade, having bought it in 2007 from EQT.

Diaverum, which serves more than 36,000 patients with a headcount of 11,000 people, could be valued at 12-13 times its expected core earnings of 150 million euros, giving it a valuation of almost 2 billion euros, the sources said.

The company's hospital network of 380 clinics in 19 countries may appeal to other private equity firms such as Advent, Bain, BC Partners, KKR and Nordic Capital, the sources said.

Industry peers such as Germany's Fresenius Medical Care and U.S.-based Davita are unlikely to bid due to antitrust concerns, while the likes of B.Braun could find its valuation challenging, the sources said.

Under Bridgepoint's ownership, Diaverum has ramped up its global presence through a string of acquisitions giving it a strong Middle East and China presence.

The private equity firm has frequently explored strategic options in the past. Most recently it opted to refinance the business in 2017 after weighing a possible sale, the sources said.

(Editing by Jan Harvey)

By Arno Schuetze and Pamela Barbaglia

Stocks mentioned in the article
ChangeLast1st jan.
DAVITA 0.49% 60.04 Delayed Quote.16.67%
EQT HOLDINGS LTD -1.41% 30.01 End-of-day quote.24.83%
FRESENIUS MEDICAL CARE AG & CO. KGAA -0.97% 63.02 Delayed Quote.11.26%
FRESENIUS SE & CO. KGAA -2.14% 44.345 Delayed Quote.6.93%
GROUPE SEB -0.21% 143.7 Real-time Quote.27.39%
JP MORGAN CHASE & COMPANY -0.40% 118.9 Delayed Quote.22.29%
KKR & CO INC 1.07% 29.15 Delayed Quote.48.50%
NORDIC GROUP LTD 0.00% 0.27 End-of-day quote.-29.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DAVITA
08/27DAVITA INC. : Schedules Capital Markets Day for September 10, 2019
08/22DAVITA : Announces Final Results Of Self-Tender Offer
08/21A FORCE FOR CHANGE : DaVita Continues to Prioritize Environmental Sustainability
08/19DAVITA : Announces Preliminary Results Of Self-Tender Offer
08/14DAVITA INC. : Entry into a Material Definitive Agreement, Creation of a Direct F..
08/12DAVITA : Announces New Senior Secured Credit Agreement
08/02DAVITA : Management's Discussion and Analysis of Financial Condition and Results..
08/01DAVITA INC. : Results of Operations and Financial Condition, Financial Statement..
08/01DAVITA INC. : 2nd Quarter 2019 Results
07/30DAVITA : Innovation in Home Care Delivery Improves the Quality of Life for More ..
More news
Financials (USD)
Sales 2019 11 350 M
EBIT 2019 1 674 M
Net income 2019 756 M
Debt 2019 6 781 M
Yield 2019 -
P/E ratio 2019 12,2x
P/E ratio 2020 11,4x
EV / Sales2019 1,33x
EV / Sales2020 1,31x
Capitalization 8 313 M
Duration : Period :
DaVita Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAVITA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 67,92  $
Last Close Price 60,04  $
Spread / Highest target 29,9%
Spread / Average Target 13,1%
Spread / Lowest Target -0,07%
EPS Revisions
Kent J. Thiry Chairman & Chief Executive Officer
Atul Mathur Executive Vice President-Global Operations
Joel Ackerman Chief Financial Officer
George R. Aronoff Chief Medical Officer
Peter Thacher Grauer Lead Independent Non-Executive Director
Sector and Competitors